Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial-onset seizures (POS). In humans and in relevant animal laboratory species,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res Perspect
Hlavní autoři: Soares-da-Silva, Patrício, Pires, Nuno, Bonifácio, Maria João, Loureiro, Ana I, Palma, Nuno, Wright, Lyndon C
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2015
Témata:
Invited Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4448990/
https://ncbi.nlm.nih.gov/pubmed/26038700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.124
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky